Fourth issued patent on technology covering at home titration and efficacy of CPAP therapy.
CleveMed, Cleveland, OH – Jan 6, 2017 – CleveMed, a leading provider of home sleep apnea testing (HSAT) solutions was issued another important patent (9,533,114) that relates to its flagship product: SleepView. The patent is entitled “Integrated Diagnostic and Therapeutic System and Method Improving Treatment of Subject with Complex and Central Sleep Apnea.” “This is our fourth issued patent on this technology covering at home titration and efficacy of CPAP therapy,” said Dr. Brian Kolkowski, CleveMed Executive Vice President and patent attorney. “We have a number of other pending patents that will further expand coverage in this upcoming significant market.”
“We are very excited about this new patent. The need to conduct a more extensive evaluation of sleep apnea therapy, especially positive airway pressure (PAP), in the home is becoming very important because it can provide physicians with comprehensive patient data cost effectively. This is especially true for millions of patients whose response to treatment can be compromised by confounding diseases that often develop over time,” said Hani Kayyali, CleveMed president.
Obstructive sleep apnea (OSA), the most prevalent form of sleep apnea, is a repeated interruption of normal breathing during sleep due to a collapse of the upper airway. It is estimated to impact as many people as asthma and diabetes; yet, up to 80 percent of the population with the disease remain undiagnosed and untreated. Moreover, OSA leads to serious health and economic consequences. Numerous studies link OSA to major chronic diseases such as stroke, heart failure, diabetes, obesity, hypertension and increased odds of serious car crash injuries. Such co-existing conditions can alter patient’s ability to benefit from sleep apnea therapy, and therefore could necessitate the re-evaluation of treatment.
CleveMed is a fast growing company with a wide range of sleep testing equipment, services, and cloud based technologies that allow sleep disorders to be monitored in the home, including Sapphire PSG™, SleepScout™, SleepView®, SleepViewSM Web-portal, and SleepView Direct. CleveMed’s goal is to expand the reach of sleep medicine with technologies that speed diagnosis for providers, reduce healthcare costs for payers, and improve patients’ experiences in the home. For more information, please visit https://CleveMed.com (Follow us on twitter, youtube, LinkedIn, and facebook). SleepView is a registered trademark and a service mark, and Sapphire PSG and SleepScout are trademarks of Cleveland Medical Devices Inc. of Cleveland, OH.